Dendritic Cell-Based Immunotherapy for Prostate Cancer
Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which display an extraordinary capacity to induce, sustain, and regulate T-cell responses providing the opportunity of DC-based cancer vaccination strategies. Thus, clinical trials enrolling prostate cancer patients were conduct...
Saved in:
| Main Authors: | Hanka Jähnisch, Susanne Füssel, Andrea Kiessling, Rebekka Wehner, Stefan Zastrow, Michael Bachmann, Ernst Peter Rieber, Manfred P. Wirth, Marc Schmitz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2010/517493 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
by: Kai Naumann, et al.
Published: (2013-01-01) -
Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration
by: Min-Seon Song, et al.
Published: (2024-01-01) -
Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy
by: Laís Teodoro Da Silva, et al.
Published: (2024-01-01) -
Cytokine-overexpressing dendritic cells for cancer immunotherapy
by: Joonsu Han, et al.
Published: (2024-12-01) -
IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT
by: A. S. Ilnitskaya, et al.
Published: (2018-07-01)